# Shared Resource: Translational BioImaging

> **NIH NIH P30** · FRED HUTCHINSON CANCER RESEARCH CENTER · 2020 · $152,388

## Abstract

PROJECT SUMMARY: TRANSLATIONAL BIOIMAGING CORE SHARED RESOURCE (TBICSR)
In vivo imaging biomarkers have become indispensable in cancer research. The Translational BioImaging Core
Shared Resource (TBICSR) provides a variety of imaging resources and support for Fred Hutch/University of
Washington Cancer Consortium research through the interdisciplinary operations of shared resources across
institutions. The goals of TBICSR are to make the widest range of high-end imaging resources available to
Consortium members in a cost effective and efficient manner. TBICSR accopmplishes this by implementing a
shared use model of imaging resources (and expertise). This is the most cost-effective way to make a wide
range of imaging resources available to Consortium members regardless of usage volume at an individual site.
Efficiency in enacting studies is enabled by allowing skilled users to access equipment via on-line scheduling
and also by providing consultation services for prospective investigators seeking advice regarding imaging
options. When consultation is requested, an imaging specialist is available to assist in Institutional Animal Care
and Use Committee (IACUC) writing, arrangement of inter-institutional transportation and housing if needed,
and system scheduling. Optimization of imaging resources is further supported through faculty imaging
modality experts that engage with investigators that desire their guidance. Imaging equipment available
through TBICSR spans the range of magnetic resonance imaging (MRI), positron emission tomography (PET),
computed tomography (CT), ultrasound (US), and optical imaging. Finally, TBICSR is supported by staff with
greater than 60 years of experience in conducting research imaging studies and in animal handling and
management. TBICSR obtained “Outstanding” ranking in the last CCSG cycle. The strengths of the resource
were and continue to be the expertise of its imaging modality leaders and the large variety of specialized major
instrumentation available to serve the imaging needs of Cancer Consortium members. In vivo imaging is an
invaluable way to non-invasively and longitudinally study the disease process and therapeutic response in
animals, which is so vital to Consortium research, prior to human studies.

## Key facts

- **NIH application ID:** 9853655
- **Project number:** 2P30CA015704-45
- **Recipient organization:** FRED HUTCHINSON CANCER RESEARCH CENTER
- **Principal Investigator:** Robert S Miyaoka
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $152,388
- **Award type:** 2
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9853655

## Citation

> US National Institutes of Health, RePORTER application 9853655, Shared Resource: Translational BioImaging (2P30CA015704-45). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9853655. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*